Tirzepatide

Tirzepatide (LY3298176)

CAS: 2023788-19-2

Class: GIP/GLP-1 receptor dual agonist; synthetic 39-amino-acid peptide conjugated to a \text{C20} fatty diacid moiety.

Form: Sterile aqueous solution prepared from tirzepatide lyophilized powder and filled into sterile empty vials (USP Type I borosilicate glass, USP-tested for sterility and endotoxins).

Solvent system: Sterile aqueous vehicle prepared using Bacteriostatic Water for Injection, USP (0.9% benzyl alcohol) as the base diluent; specific components vary by manufacturer; for research use only, not for parenteral administration.

Manufacturing: Prepared under cGMP-aligned, ISO-compliant procedures for research-grade peptides. No release specifications exist for clinical, diagnostic, or veterinary use.

Intended use: For research use only (RUO). For in vitro laboratory applications such as receptor binding, signaling, and metabolic pathway studies. Not for use in humans or animals, or in clinical, diagnostic, or preclinical safety studies.

Storage and handling: Store vials refrigerated at 2–8 \mathrm{^\circ C}; protect from light and do not freeze. Use aseptic technique when accessing the vial. Once first opened, use within 21 days and discard any unused portion.

Disclaimer: This product has not been evaluated or approved by FDA, EMA, or any other regulatory authority for therapeutic, diagnostic, or veterinary use. Sterility and quality controls are appropriate for RUO materials only and are not qualified to any drug-product or medical-device standard.